共 267 条
[51]
Sohn I(2018)New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm Gut 67 1674-1316
[52]
Ahn HS(2014)The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation? J BUON 19 398-704
[53]
Khoo E(2017)From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world World J Gastroenterol 23 5282-397
[54]
O'Neill S(2013)Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants Eur J Radiol 82 e212-1221
[55]
Brown E(2009)Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 616-194
[56]
Wigmore SJ(2011)EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 1309-222
[57]
Harrison EM(2011)Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation J Hepatol 54 695-979
[58]
Mitchell D(2014)Comparison of RECIST, mRECIST, and Choi criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads J Comput Assist Tomogr 38 391-73
[59]
Puckett Y(2017)Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology J Hepatol 67 1213-4481
[60]
Nguyen QN(2020)Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma Eur Radiol 30 186-386